Phibro Animal Health (NASDAQ:PAHC) Price Target Raised to $20.00 at Barclays

Phibro Animal Health (NASDAQ:PAHC) had its target price lifted by equities researchers at Barclays from $13.00 to $20.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price target indicates a potential downside of 20.85% from the company’s current price.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price for the company. Bank of America raised their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Stock Up 0.8 %

PAHC opened at $25.27 on Tuesday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of 58.77, a price-to-earnings-growth ratio of 0.66 and a beta of 0.51. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The firm’s fifty day moving average is $22.57 and its 200 day moving average is $19.61. Phibro Animal Health has a fifty-two week low of $9.49 and a fifty-two week high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The business had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. On average, sell-side analysts forecast that Phibro Animal Health will post 1.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the acquisition, the director now directly owns 25,000 shares in the company, valued at approximately $500,500. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 50.07% of the stock is owned by company insiders.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of PAHC. CWM LLC raised its holdings in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock valued at $37,000 after buying an additional 1,035 shares during the period. nVerses Capital LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth about $70,000. Quantbot Technologies LP purchased a new position in shares of Phibro Animal Health during the 3rd quarter worth about $70,000. Summit Securities Group LLC bought a new position in Phibro Animal Health during the 2nd quarter valued at about $83,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Phibro Animal Health by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.